FOR IMMEDIATE RELEASE
- Second São Paulo congress of 2026 runs November 20–21, following ISSCA’s April program in the city
- Additional congress reflects Brazil’s position as one of ISSCA’s highest-priority Latin American markets
- Event runs alongside Cellgenic’s permanent operations launch in Brazil
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 127, its second São Paulo, Brazil congress of 2026, taking place November 20–21 in the city’s Vila Olímpia district, following ISSCA’s first 2026 Brazil program in April.
Running two Brazil events in a single year is a frequency ISSCA has not previously applied to the market, reflecting Brazil’s scale and the organization’s broader Latin American expansion alongside Cellgenic’s commercial buildout.
The second São Paulo congress runs alongside Cellgenic’s establishment of permanent operations in Brazil, reinforcing ISSCA and Cellgenic’s coordinated market presence in one of Latin America’s largest healthcare markets.
“Brazil earned a second date on our calendar this year,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Between ISSCA’s education programming and Cellgenic’s commercial buildout, Brazil is becoming one of our most active single markets anywhere in the world.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
